<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760266</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2411</org_study_id>
    <nct_id>NCT00760266</nct_id>
  </id_info>
  <brief_title>Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population</brief_title>
  <acronym>ACTION</acronym>
  <official_title>An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of initial use of a fixed
      dose combination of aliskiren Hydrochlorothiazide (HCTZ) compared to Hydrochlorothiazide in
      older population with Stage 2 systolic hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (in Patients With msDBP ≥90 mmHg at Baseline) From Baseline to Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Week 4 and Week 8</measure>
    <time_frame>At 4 weeks and 8 weeks</time_frame>
    <description>Responders defined as mean sitting Systolic Blood Pressure &lt; 140 mmHg or reduction of ≥ 20 mmHg from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Blood Pressure Control at Weeks 4 and 8</measure>
    <time_frame>At Weeks 4 and 8</time_frame>
    <description>Blood pressure control defined as mean sitting Systolic Blood Pressure &lt; 140 mm Hg and mean sitting Diastolic Blood Pressure &lt; 90 mm Hg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren/HCTZ 300/25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks</description>
    <arm_group_label>Aliskiren/HCTZ 300/25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks</description>
    <arm_group_label>HCTZ 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients, ≥ 55 years old

          2. Patients with essential hypertension

          3. Prior to randomization: Patients must have an office cuff mean sitting Systolic Blood
             Pressure ≥ 160 mm Hg and &lt; 200 mm Hg

          4. Patients who are eligible and able to participate in the study, and who are willing to
             give informed consent before any assessment is performed

        Exclusion Criteria:

          1. Office blood pressure measured by cuff (msSBP ≥ 200 mm Hg and/or msDBP ≥ 110 mm Hg) at
             Visits 1-5

          2. History or evidence of a secondary hypertension of any etiology (e.g., uncorrected
             renal artery stenosis, pheochromocytoma).

          3. History of hypertensive encephalopathy or heart failure (New York Heart Association
             [NYHA] Class II-IV)

          4. Cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial
             infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI)
             within 1 year prior to Visit 1

          5. Serum sodium less than the lower limit of normal, serum potassium &lt; 3.5 mEq/L
             (corresponding to 3.5 mmol/L) or ≥ 5.3 mEq/L (corresponding to 5.3 mmol/L), or
             dehydration at Visit 1.

          6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 5 mIU/mL)

          7. Use of other investigational drugs within 30 days of enrollment.

        Other exclusions may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sites in USA</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bloodpressureresearch.com</url>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>December 22, 2010</results_first_submitted>
  <results_first_submitted_qc>December 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2011</results_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>older population</keyword>
  <keyword>aliskiren</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>systolic blood pressure</keyword>
  <keyword>diastolic blood pressure</keyword>
  <keyword>amlodipine, stage 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren/HCTZ</title>
          <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
        </group>
        <group group_id="P2">
          <title>HCTZ</title>
          <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren/HCTZ</title>
          <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
        </group>
        <group group_id="B2">
          <title>HCTZ</title>
          <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="7.57"/>
                    <measurement group_id="B2" value="65.1" spread="6.96"/>
                    <measurement group_id="B3" value="64.8" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 4</title>
          <population>Full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.6" spread="1.0"/>
                    <measurement group_id="O2" value="-22.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full analysis set, restricted to baseline msDBP &gt;= 90 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 4</title>
          <population>Full analysis set, restricted to baseline msDBP &gt;= 90 mmHg</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="0.8"/>
                    <measurement group_id="O2" value="-9.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (in Patients With msDBP ≥90 mmHg at Baseline) From Baseline to Week 8</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set, restricted for msDBP to those with baseline msDBP at least 90 mm Hg)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (in Patients With msDBP ≥90 mmHg at Baseline) From Baseline to Week 8</title>
          <population>Full analysis set, restricted for msDBP to those with baseline msDBP at least 90 mm Hg)</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>msSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.2" spread="1.0"/>
                    <measurement group_id="O2" value="-25.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>msDBP (N = 130 , 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="0.8"/>
                    <measurement group_id="O2" value="-10.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Week 4 and Week 8</title>
        <description>Responders defined as mean sitting Systolic Blood Pressure &lt; 140 mmHg or reduction of ≥ 20 mmHg from baseline</description>
        <time_frame>At 4 weeks and 8 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Week 4 and Week 8</title>
          <description>Responders defined as mean sitting Systolic Blood Pressure &lt; 140 mmHg or reduction of ≥ 20 mmHg from baseline</description>
          <population>Full analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1"/>
                    <measurement group_id="O2" value="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving Blood Pressure Control at Weeks 4 and 8</title>
        <description>Blood pressure control defined as mean sitting Systolic Blood Pressure &lt; 140 mm Hg and mean sitting Diastolic Blood Pressure &lt; 90 mm Hg</description>
        <time_frame>At Weeks 4 and 8</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/HCTZ</title>
            <description>Aliskiren / Hydrochlorothiazide (HCTZ) 150/12.5 mg: 1 week, Aliskiren / HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
          </group>
          <group group_id="O2">
            <title>HCTZ</title>
            <description>Hydrochlorothiazide (HCTZ) 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Blood Pressure Control at Weeks 4 and 8</title>
          <description>Blood pressure control defined as mean sitting Systolic Blood Pressure &lt; 140 mm Hg and mean sitting Diastolic Blood Pressure &lt; 90 mm Hg</description>
          <population>Full analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One patient was excluded from this analysis as he/she was inadvertently randomized into the study but did not receive study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren / HCTZ</title>
          <description>Aliskiren HCTZ 150/12.5 mg: 1 week, Aliskiren HCTZ 300/25 mg (with or without amlodipine): 7 weeks</description>
        </group>
        <group group_id="E2">
          <title>HCTZ</title>
          <description>HCTZ 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

